Search for companies, drugs, and catalysts
Phase 2
Development Phase
2
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
Ruxolitinib Phase 3 Results Expected
Ruxolitinib • MPN (Myeloproliferative Neoplasms)
Ruxolitinib Phase 2 Results Expected
Target Indication
MPN (Myeloproliferative Neoplasms)
Clinical Trial
Last updated: 12/4/2025
INCY
Incyte Corporation